UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

FORM 8-K
CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
June 4, 2007
 
Targeted Genetics Corporation
(Exact name of registrant as specified in its charter)
 
Washington
0-23930
91-1549568
(State or other jurisdiction
of incorporation)
(Commission File
Number)
(IRS Employer
Identification No.)
 
1100 Olive Way, Suite 100, Seattle, Washington
98101
(Address of principal executive offices)
(Zip Code)
 
Registrant's telephone number, including area code
(206) 623-7612
 
Not Applicable
(Former name or former address if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
Item 8.01. Other Events.

On June 4, 2007, Targeted Genetics Corporation announced that it had reported additional data from the dose escalation arm of the ongoing Phase I/II clinical study of tgAAC94 in patients with inflammatory arthritis. A copy of the press release announcing this data and describing the Phase I/II trial is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.
 
Item 9.01. Financial Statements and Exhibits.

    Exhibits.

99.1    
Press Release of Targeted Genetics Corporation dated June 4, 2007.
 
SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
 
Targeted Genetics Corporation
 
 		  
 		  
 
  By:   /s/ David J. Poston
 
David J. Poston 
 
Vice President and
Chief Financial Officer 
 
Dated: June 4, 2007
 
 
INDEX TO EXHIBITS

Exhibit
Number
 
Description
 
 
 
99.1
 
Press Release of Targeted Genetics Corporation dated June 4, 2007